Shots:

• The EUA is based on ACCT-2 study assessing baricitinib (4mg- qd for 14 days or until hospital discharge) in combination with remdesivir vs PBO with remdesivir in hospitalized patients with/ out oxygen requirements
• Result: Median time to recovery from 8-7days (12.5% improvement)- patients who progressed to ventilation (23% vs 28%)- patients who died @day29 (4.7% vs 7.1%) with a relative reduction of 35%; better clinical status @day15
• This marks the second Lilly therapy to be granted a EUA- in addition to neutralizing Ab EUA for high-risk non-hospitalized patients- increasing the number of treatment options for COVID-19 patients at different stages of the disease

 ­ Ref: Eli Lilly | Image: Eli Lilly